恩瑞格的疗效如何呢？

Indications: 1. Patients with chronic iron overload transfusion hemosiderinosis secondary to blood transfusion who are 2 years old or older will develop chronic iron overload symptoms when serum ferritin continues to be >1000 L, and iron chelation therapy should be started at this time; 2. Patients receiving ASCT can also be given iron chelate therapy when iron overload occurs; 3. It can be used to treat reversible renal insufficiency caused by Fanconi syndrome. Today let’s take a look at the efficacy of Enrige?

Enrig is more convenient and has higher patient compliance. EPIC is currently the largest prospective, open, single-group, global multi-center clinical study designed for patients with iron overload. A total of 341 MDS patients were enrolled, and it could reduce serum ferritin by an average of 372 μg/L in 3 months. Iron overload increases the risk of infection, endocrine system damage, vital organ dysfunction, AML transformation in MDS patients, and shortens survival. Iron chelators are currently the mainstream treatment for iron removal. Among them, Enrige is easy to administer, significantly reduces ferritin levels, and has a definite effect in protecting important target organ systems such as the liver, heart, and endocrine system. It is currently the preferred option for iron removal treatment.

The benefits of iron removal therapy are not only reflected in the reduction of ferritin levels, but also can improve the patient's hematological response, stabilize and reverse the patient's liver fibrosis, improve the ejection fraction of the heart, and prevent the occurrence of important cardiac events such as heart failure and arrhythmia. Our country’s data also supports the above conclusion. The results of a single-arm, multi-center, prospective clinical study involving 64 AA patients with transfusion-related iron overload confirmed the effectiveness and safety of Enrig in reducing patients' ferritin levels. A prospective, observational study in my country using liver, pancreas, and heart as monitoring indicators confirmed that Enrig can improve organ function in patients with iron overload. The results of the TELESTO study released at the ASH 2018 meeting also proved that Enrige continuously reduces serum ferritin levels, while reducing the risk of heart function damage, liver function damage, transformation to leukemia and other events by 36.4%.

The above is the content of the therapeutic effect, I hope it can help you!